文献速递腹部MR

提高LI-RADS v2018在细胞外对比剂增强MRI上诊断小(10-19 mm)肝细胞癌的敏感度

Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
PubMed 文献 · Abdom Radiol (NY) · 2020-10-11

回顾性分析167例高危患者174个小观察灶的细胞外对比剂增强MRI,两位放射科医师用LI-RADS v2018及四个逐步扩展LR-5标准的修改版本评分。将LR-5标准扩展为包含非环状动脉期高强化加至少一个其他主要特征,或无动脉期高强化加至少两个其他主要特征,可显著提高小肝癌诊断敏感度而不显著降低特异度,原文认为需多中心前瞻性研究确认。

要点

  • LI-RADS v2018的LR-5标准对小肝癌(10-19 mm)敏感度70%、特异度95%(两位读者一致)。
  • 扩展LR-5标准至非环状APHE加至少1个其他主要特征,敏感度升至75%/75%(读者1/读者2),特异度90%/92%,特异度降低未达统计学显著。
  • 扩展LR-5标准至无APHE加至少2个其他主要特征,敏感度升至78%/79%,特异度90%/92%,特异度降低未达统计学显著。

核心结论

  • 将v2018 LR-5标准扩展为包含非环状APHE加至少一个其他主要特征,或无APHE加至少两个其他主要特征,可显著提高小肝癌诊断敏感度而不显著降低特异度,原文认为需多中心前瞻性研究确认。

研究设计与样本

  • 回顾性研究纳入2014至2018年167例连续高危患者的174个细胞外对比剂增强MRI小观察灶,对每个观察灶采用最佳可用参考标准,两位放射科医师在不知参考标准的情况下评分LI-RADS影像特征并分别按v2018及四个逐步扩展LR-5标准的修改版本(mLI-RADS I至IV)分类。

关键影像表现/征象

  • 174个观察灶中包括135个肝细胞癌、8个非肝细胞癌恶性肿瘤和31个良性病变。
  • 使用LI-RADS v2018时,LR-5诊断小肝癌的敏感度为70%(两位读者一致),特异度为95%(两位读者一致)。

诊断标准与关键数值

  • LI-RADS v2018的LR-5:敏感度70%(两位读者),特异度95%(两位读者)。
  • mLI-RADS I(非环状APHE加至少1个其他主要特征):读者1敏感度75%、读者2敏感度75% vs 70%(p=0.016/0.031),读者1特异度90%、读者2特异度92% vs 95%(p=0.500/1.000)。
  • mLI-RADS II(无APHE加至少2个其他主要特征):读者1敏感度78%、读者2敏感度79% vs 70%(p=0.001/0.001),读者1特异度90%、读者2特异度92% vs 95%(p=0.500/1.000)。
  • mLI-RADS III:读者1敏感度80%、读者2敏感度81% vs 70%(p<0.001/<0.001),读者1特异度85%、读者2特异度80% vs 95%(p=0.125/0.063,趋势水平降低)。
  • mLI-RADS IV:读者1敏感度94%、读者2敏感度92% vs 70(p<0.001/<0.001),读者1特异度64%、读者2特异度62% vs 95%(p<0.001/<0.001,显著降低)。

临床应用与阅片要点

  • 对10-19 mm小观察灶,按v2018 LR-5标准判读时敏感度有限,扩展标准(mLI-RADS I或II)可在不显著降低特异度的情况下提高敏感度。
  • 扩展标准mLI-RADS III和IV进一步提高敏感度,但特异度呈趋势水平或显著降低,原文未据此给出推荐。

局限性

  • 原文结论指出需多中心前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate whether the LI-RADS v2018 LR-5 criteria can be modified to increase sensitivity without reducing specificity for diagnosing small (10-19 mm) HCC.

METHODS: 167 consecutive high-risk patients with 174 small observations reported clinically on extracellular contrast-enhanced MRI from 2014 to 2018 were retrospectively studied. The best available reference standard was applied for each observation. Blinded to the reference standard, two radiologists scored LI-RADS imaging features retrospectively and assigned each observation a LI-RADS category using LI-RADS v2018 and each of four modified LI-RADS versions (mLI-RADS I to IV) with successively more expansive LR-5 criteria. Per-observation sensitivity and specificity of LR-5 for small HCC using each version were assessed. Each modified version was compared to v2018 (McNemar test).

RESULTS: The 174 observations included 135 HCC, 8 non-HCC malignancies, and 31 benign entities. Using LI-RADS v2018, LR-5 provided 70% (both readers) sensitivity and 95% (both readers) specificity for small HCC. Expanding the LR-5 criteria to include nonrim APHE plus at least one additional major feature (mLI-RADS I) or no APHE plus at least two additional major features (mLI-RADS II) significantly increased sensitivity (reader 1/reader 2: 75%/75% vs. 70%, p = 0.016/0.031; 78%/79% vs. 70%, p = 0.001/0.001) without significantly reducing specificity (reader 1/reader 2: 90%/92% vs. 95%, p = 0.500/1.000 for both). mLI-RADS III and IV further increased sensitivity (reader 1/reader 2: 80%/81% vs. 70%, p < 0.001/< 0.001; 94%/92% vs. 70, p < 0.001/< 0.001) but with trend-level (reader 1/reader 2: 85%/80% vs. 95%, p = 0.125/0.063) or significant (reader 1/reader 2: 64%/62% vs. 95%, p < 0.001/< 0.001) specificity reductions.

CONCLUSIONS: Expanding the v2018 LR-5 criteria to include nonrim APHE plus at least one additional major feature or no APHE plus at least two additional major features significantly increases sensitivity without significantly reducing specificity for small HCC. Confirmation is warranted in multi-center prospective studies.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Chen J, Kuang S, Zhang Y, et al. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI. Abdom Radiol (NY). 2020. PMID: 33040166. doi:10.1007/s00261-020-02790-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。